搜索
Pharvaris NV
PHVS添加自选
33.950USD
-0.630-1.82%
收盘 07/01, 16:00（美东）报价延迟15分钟
2.22B总市值
亏损市盈率 TTM
关于 Pharvaris NV 公司
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Pharvaris NV简介
公司代码PHVS
公司名称Pharvaris NV
上市日期Feb 05, 2021
CEOModig (Berndt B.A.E)
员工数量- -
证券类型Ordinary Share
年结日Feb 05
公司地址Emmy Noetherweg 2
城市LEIDEN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Netherlands
邮编2333 BK
电话31712036410
网址https://pharvaris.com/
公司代码PHVS
上市日期Feb 05, 2021
CEOModig (Berndt B.A.E)
Pharvaris NV公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
47.61K
-5.61%
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
常见问题
Pharvaris NV的前五大股东是谁？
Pharvaris NV 的前五大股东如下：Mr. Berndt Modig, CPA
有多少机构持有Pharvaris NV(PHVS)的股份？
截至2026Q1，共有165家机构持有Pharvaris NV的股份，合计持有的股份价值约为59.26M，占公司总股份的90.60%。与2025Q4相比，机构持股有所增加，增幅为-451327.00。